BioNexus Gene Lab Corp. (BGLC) announced it has received official notification from The Nasdaq Stock Market LLC, confirming the company has regained full compliance with Nasdaq Listing Rule 5550(a)(2). This rule requires a minimum bid price of $1.00 per share. This achievement follows the company's 1-for-10 reverse stock split effected on April 7, 2025.
Regaining Nasdaq compliance is a crucial milestone that reaffirms BGLC’s standing as a compliant public company. This allows the company to pursue its innovation roadmap, engage with capital markets, and execute international expansion plans. The Nasdaq listing is a cornerstone of BGLC's long-term strategy, providing global visibility, investor confidence, and access to institutional capital.
In parallel with achieving compliance, BGLC has strengthened its corporate governance by appointing new independent board members and forming a dedicated internal audit function. The company also retained U.S.-based investment banking support for long-term value creation initiatives. These steps position BGLC for strategic partnerships, capital raising, and M&A activity.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.